JP2016528882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528882A5 JP2016528882A5 JP2016521907A JP2016521907A JP2016528882A5 JP 2016528882 A5 JP2016528882 A5 JP 2016528882A5 JP 2016521907 A JP2016521907 A JP 2016521907A JP 2016521907 A JP2016521907 A JP 2016521907A JP 2016528882 A5 JP2016528882 A5 JP 2016528882A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YCBIWVHDKSQGFJ-UHFFFAOYSA-N C(C1)C11OCCCC1 Chemical compound C(C1)C11OCCCC1 YCBIWVHDKSQGFJ-UHFFFAOYSA-N 0.000 description 2
- BVJWKTOWLQBIRD-UHFFFAOYSA-N C1OC11NCCOC1 Chemical compound C1OC11NCCOC1 BVJWKTOWLQBIRD-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838534P | 2013-06-24 | 2013-06-24 | |
| US61/838,534 | 2013-06-24 | ||
| PCT/US2014/043952 WO2014210064A1 (en) | 2013-06-24 | 2014-06-24 | Anti-fcrh5 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019192491A Division JP2020048559A (ja) | 2013-06-24 | 2019-10-23 | 抗ＦｃＲＨ５抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528882A JP2016528882A (ja) | 2016-09-23 |
| JP2016528882A5 true JP2016528882A5 (https=) | 2017-08-10 |
| JP6684208B2 JP6684208B2 (ja) | 2020-04-22 |
Family
ID=51212984
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521907A Active JP6684208B2 (ja) | 2013-06-24 | 2014-06-24 | 抗ＦｃＲＨ５抗体 |
| JP2019192491A Pending JP2020048559A (ja) | 2013-06-24 | 2019-10-23 | 抗ＦｃＲＨ５抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019192491A Pending JP2020048559A (ja) | 2013-06-24 | 2019-10-23 | 抗ＦｃＲＨ５抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10435471B2 (https=) |
| EP (3) | EP3736291B1 (https=) |
| JP (2) | JP6684208B2 (https=) |
| KR (1) | KR20160022912A (https=) |
| CN (2) | CN105473618A (https=) |
| AR (1) | AR096687A1 (https=) |
| AU (2) | AU2014302617B2 (https=) |
| BR (1) | BR112015032224B1 (https=) |
| CA (1) | CA2915480C (https=) |
| DK (3) | DK3013861T3 (https=) |
| ES (3) | ES2962874T3 (https=) |
| FI (1) | FI3736291T3 (https=) |
| HK (1) | HK1222663A1 (https=) |
| HR (3) | HRP20180352T1 (https=) |
| HU (3) | HUE036581T2 (https=) |
| IL (2) | IL243129B (https=) |
| LT (3) | LT3013861T (https=) |
| MX (1) | MX376663B (https=) |
| MY (2) | MY176285A (https=) |
| NO (1) | NO2955475T3 (https=) |
| PL (3) | PL3013861T3 (https=) |
| PT (3) | PT3336106T (https=) |
| RS (3) | RS60418B1 (https=) |
| RU (2) | RU2687132C2 (https=) |
| SG (2) | SG10201804338PA (https=) |
| SI (3) | SI3013861T1 (https=) |
| TW (1) | TWI725931B (https=) |
| WO (1) | WO2014210064A1 (https=) |
| ZA (2) | ZA201509261B (https=) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| KR20170066421A (ko) | 2014-09-12 | 2017-06-14 | 제넨테크, 인크. | 항-cll-1 항체 및 면역접합체 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| WO2016090337A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| SG10202006863YA (en) | 2015-02-16 | 2020-08-28 | Lonza Ag | Cl and/or ch1 mutated antibodies for drug conjugation |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| TWI731861B (zh) * | 2015-06-16 | 2021-07-01 | 美商建南德克公司 | FcRH5之人源化及親和力成熟抗體及使用方法 |
| EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| EP3322801A1 (en) | 2015-07-15 | 2018-05-23 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| KR20180089497A (ko) | 2015-12-04 | 2018-08-08 | 메모리얼 슬로안-케터링 캔서 센터 | Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법 |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| EP3548515B1 (en) | 2016-12-01 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| CA3053348A1 (en) | 2017-02-10 | 2018-08-16 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| KR102880156B1 (ko) | 2017-07-24 | 2025-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 항cd8 항체 및 이의 용도 |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| AU2018358067A1 (en) | 2017-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
| EP3704230B1 (en) | 2017-11-01 | 2024-10-23 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| SG11202003657VA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Process for producing a t cell composition |
| JP7447006B2 (ja) | 2017-11-01 | 2024-03-11 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体 |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| WO2019113557A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| JP7433230B2 (ja) | 2017-12-08 | 2024-02-19 | ジュノー セラピューティクス インコーポレイテッド | 細胞を培養するための無血清培地配合物およびその使用の方法 |
| CA3084446A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EA202190469A1 (ru) | 2018-08-09 | 2021-06-28 | Джуно Терапьютикс, Инк. | Способы оценки интегрированных нуклеиновых кислот |
| KR20210113169A (ko) | 2018-11-01 | 2021-09-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법 |
| MA54079A (fr) | 2018-11-01 | 2021-09-08 | Juno Therapeutics Inc | Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g) |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| AU2020265741A1 (en) | 2019-05-01 | 2021-11-25 | Editas Medicine, Inc. | Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods |
| EP3962519A1 (en) | 2019-05-01 | 2022-03-09 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| KR20230009386A (ko) | 2020-04-10 | 2023-01-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도 |
| JP7727662B2 (ja) | 2020-05-13 | 2025-08-21 | ジュノー セラピューティクス インコーポレイテッド | 臨床応答に関連する特徴量の特定方法およびその使用 |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| KR20230100732A (ko) | 2020-11-04 | 2023-07-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이성 항체의 피하 투여 |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| CA3199830A1 (en) | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
| JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法およびｄｇｋ阻害剤の組合せ |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| US20250283037A1 (en) | 2021-05-06 | 2025-09-11 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| JP2025504002A (ja) | 2022-01-28 | 2025-02-06 | ジュノー セラピューティクス インコーポレイテッド | 細胞組成物を製造する方法 |
| MX2024010003A (es) | 2022-02-18 | 2024-09-30 | Rakuten Medical Inc | Moléculas de anticuerpo anti-ligando 1 de muerte programada (pd-l1), polinucleótidos que las codifican y métodos de uso. |
| TWI882313B (zh) | 2022-04-13 | 2025-05-01 | 美商建南德克公司 | 治療性蛋白質之醫藥組成物及使用方法 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| CN120152717A (zh) | 2022-09-08 | 2025-06-13 | 朱诺治疗学股份有限公司 | T细胞疗法和连续或间歇dgk抑制剂给药的组合 |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | 诺华股份有限公司 | 慢病毒配制品 |
| CN117384299B (zh) * | 2022-11-01 | 2024-04-30 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 靶向bcma和/或fcrh5的嵌合抗原受体、car-t细胞及其应用 |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN121100267A (zh) | 2022-12-09 | 2025-12-09 | 朱诺治疗学股份有限公司 | 使用全息成像预测细胞表型的机器学习方法 |
| CN121002052A (zh) | 2023-02-03 | 2025-11-21 | C3S2 有限公司 | 用于非病毒生产工程化免疫细胞的方法 |
| CN116789849B (zh) * | 2023-04-12 | 2024-03-08 | 南京紫珑生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| WO2025032254A1 (en) * | 2023-08-10 | 2025-02-13 | Astrazeneca Ab | Anthracycline derivatives and conjugates and uses thereof |
| WO2025213043A1 (en) * | 2024-04-04 | 2025-10-09 | Translational Sciences, Inc. | Matrix metalloproteinase-9 inhibitor and treatment of stroke |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| KR100332254B1 (ko) | 1993-10-01 | 2002-09-27 | 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 | 신규인펩티드유도체 |
| US7074897B2 (en) | 1997-06-16 | 2006-07-11 | Genentech, Inc. | Pro943 polypeptides |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| US7105149B1 (en) | 1999-11-29 | 2006-09-12 | The Trustees Of Columbia University In The City Of New York | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma |
| EP1235847B1 (en) | 1999-11-29 | 2016-01-20 | The Trustees of Columbia University in the City of New York | ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA |
| US20040005561A1 (en) | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| AU2002329540A1 (en) | 2001-06-20 | 2003-01-02 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1487877B1 (en) | 2001-09-18 | 2010-10-27 | Genentech, Inc. | Compositions and methods for the diagnosis of tumors |
| US20050226869A1 (en) | 2001-10-19 | 2005-10-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7888478B2 (en) | 2002-09-11 | 2011-02-15 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| US7858330B2 (en) | 2001-10-19 | 2010-12-28 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| EP1696963A2 (en) | 2003-12-24 | 2006-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| EP1718667B1 (en) * | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| WO2006039238A2 (en) * | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| US20080247944A1 (en) | 2005-01-12 | 2008-10-09 | Robert Graziano | Irta-2 Antibodies and Their Uses |
| NZ563370A (en) | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| WO2008109533A2 (en) | 2007-03-02 | 2008-09-12 | Medarex, Inc. | Human antibodies that bind multiple irta family proteins, and uses thereof |
| US8742076B2 (en) * | 2008-02-01 | 2014-06-03 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| CN102159248B (zh) * | 2008-07-15 | 2013-09-11 | 健泰科生物技术公司 | 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途 |
| MX2011010265A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
| WO2010120561A1 (en) * | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| US8728730B2 (en) | 2009-09-03 | 2014-05-20 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| DK2528625T3 (da) * | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| UA129760C2 (uk) | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| TWI731861B (zh) | 2015-06-16 | 2021-07-01 | 美商建南德克公司 | FcRH5之人源化及親和力成熟抗體及使用方法 |
-
2014
- 2014-06-23 TW TW103121621A patent/TWI725931B/zh active
- 2014-06-23 AR ARP140102352A patent/AR096687A1/es unknown
- 2014-06-24 LT LTEP14742047.5T patent/LT3013861T/lt unknown
- 2014-06-24 CN CN201480045475.0A patent/CN105473618A/zh active Pending
- 2014-06-24 US US14/313,822 patent/US10435471B2/en active Active
- 2014-06-24 PT PT171984156T patent/PT3336106T/pt unknown
- 2014-06-24 HU HUE14742047A patent/HUE036581T2/hu unknown
- 2014-06-24 ES ES20169942T patent/ES2962874T3/es active Active
- 2014-06-24 SG SG10201804338PA patent/SG10201804338PA/en unknown
- 2014-06-24 CN CN202211286136.4A patent/CN116063515A/zh active Pending
- 2014-06-24 CA CA2915480A patent/CA2915480C/en active Active
- 2014-06-24 SI SI201430602T patent/SI3013861T1/en unknown
- 2014-06-24 KR KR1020167001897A patent/KR20160022912A/ko not_active Ceased
- 2014-06-24 PT PT147420475T patent/PT3013861T/pt unknown
- 2014-06-24 PL PL14742047T patent/PL3013861T3/pl unknown
- 2014-06-24 EP EP20169942.8A patent/EP3736291B1/en active Active
- 2014-06-24 LT LTEP20169942.8T patent/LT3736291T/lt unknown
- 2014-06-24 RS RS20200733A patent/RS60418B1/sr unknown
- 2014-06-24 BR BR112015032224-7A patent/BR112015032224B1/pt active IP Right Grant
- 2014-06-24 WO PCT/US2014/043952 patent/WO2014210064A1/en not_active Ceased
- 2014-06-24 HR HRP20180352TT patent/HRP20180352T1/hr unknown
- 2014-06-24 HK HK16110816.3A patent/HK1222663A1/zh unknown
- 2014-06-24 PL PL17198415T patent/PL3336106T3/pl unknown
- 2014-06-24 HU HUE20169942A patent/HUE063910T2/hu unknown
- 2014-06-24 PT PT201699428T patent/PT3736291T/pt unknown
- 2014-06-24 RS RS20230745A patent/RS64514B1/sr unknown
- 2014-06-24 ES ES17198415T patent/ES2812243T3/es active Active
- 2014-06-24 RU RU2016101965A patent/RU2687132C2/ru active
- 2014-06-24 JP JP2016521907A patent/JP6684208B2/ja active Active
- 2014-06-24 SI SI201431623T patent/SI3336106T1/sl unknown
- 2014-06-24 FI FIEP20169942.8T patent/FI3736291T3/fi active
- 2014-06-24 DK DK14742047.5T patent/DK3013861T3/da active
- 2014-06-24 HR HRP20231323TT patent/HRP20231323T1/hr unknown
- 2014-06-24 HU HUE17198415A patent/HUE049446T2/hu unknown
- 2014-06-24 EP EP17198415.6A patent/EP3336106B1/en active Active
- 2014-06-24 MX MX2015017331A patent/MX376663B/es active IP Right Grant
- 2014-06-24 RU RU2019109452A patent/RU2019109452A/ru unknown
- 2014-06-24 DK DK17198415.6T patent/DK3336106T3/da active
- 2014-06-24 PL PL20169942.8T patent/PL3736291T3/pl unknown
- 2014-06-24 LT LTEP17198415.6T patent/LT3336106T/lt unknown
- 2014-06-24 SI SI201432050T patent/SI3736291T1/sl unknown
- 2014-06-24 MY MYPI2015704672A patent/MY176285A/en unknown
- 2014-06-24 RS RS20180149A patent/RS56878B1/sr unknown
- 2014-06-24 EP EP14742047.5A patent/EP3013861B1/en active Active
- 2014-06-24 AU AU2014302617A patent/AU2014302617B2/en active Active
- 2014-06-24 DK DK20169942.8T patent/DK3736291T5/da active
- 2014-06-24 SG SG11201510653YA patent/SG11201510653YA/en unknown
- 2014-06-24 ES ES14742047.5T patent/ES2659229T3/es active Active
-
2015
- 2015-05-08 NO NO15001398A patent/NO2955475T3/no unknown
- 2015-12-15 IL IL243129A patent/IL243129B/en active IP Right Grant
- 2015-12-18 ZA ZA2015/09261A patent/ZA201509261B/en unknown
-
2018
- 2018-12-14 ZA ZA2018/08451A patent/ZA201808451B/en unknown
-
2019
- 2019-01-31 MY MYPI2019000547A patent/MY191169A/en unknown
- 2019-09-23 IL IL26952819A patent/IL269528A/en unknown
- 2019-09-26 US US16/583,584 patent/US11352431B2/en active Active
- 2019-10-23 JP JP2019192491A patent/JP2020048559A/ja active Pending
-
2020
- 2020-03-17 AU AU2020201918A patent/AU2020201918A1/en not_active Abandoned
- 2020-07-15 HR HRP20201111TT patent/HRP20201111T1/hr unknown
-
2022
- 2022-05-02 US US17/734,239 patent/US20230096941A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528882A5 (https=) | ||
| RU2016101965A (ru) | Анти-fcrh5 антитела | |
| JP2019146572A5 (https=) | ||
| JP2016523810A5 (https=) | ||
| JP2017522861A5 (https=) | ||
| JP7401126B2 (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| JP2015523961A5 (https=) | ||
| JP2017534253A5 (https=) | ||
| JP7099957B2 (ja) | ヒト化、マウスまたはキメラ抗ｃｄ４７モノクローナル抗体 | |
| JP2015523380A5 (https=) | ||
| RU2014148162A (ru) | Анти-pmel17 антитела и их иммуноконъюгаты | |
| JP2017534256A5 (https=) | ||
| JP2014509835A5 (https=) | ||
| JP2015528818A5 (https=) | ||
| RU2016133846A (ru) | Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения | |
| JP2017514461A5 (https=) | ||
| JP2016098233A5 (https=) | ||
| JP2018021031A (ja) | Ｃｄ２７ｌ抗原結合タンパク質 | |
| JP2009536921A5 (https=) | ||
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| CN115969970A (zh) | Abcg2抑制剂与sacituzumab govitecan的组合 | |
| JP2017535257A5 (https=) | ||
| RU2016150370A (ru) | Антитела и иммуноконъюгаты против GPC3 | |
| IL278574B2 (en) | Glycan-interacting compounds and methods of use | |
| TW201620553A (zh) | 抗ｃｄ９８抗體－藥物結合物 |